IRF7 and brain neoplasm: Consistent with previous reports, irf8 knock-down resulted in significant reductions in neutral red-positive phagocytes at 8–10 dpf (Figure 4—figure supplement 2; Shiau et al., 2015), and while no significant differences in neutral red-positive phagocyte number were observed following irf7 gene targeting, irf7 CRISPR/Cas9-injected animals displayed early mortality un-related to brain tumor formation, with ~80% of CRISPR-injected animals displaying illness prior to 2 months of age, consistent with a broad requirement for Irf7 in immune responses, among other functions.